A retrospective study by Mao et al. of 295 people with stage II CRC showed that patients with POLE mutations were more prone to lymphovascular invasion (55.6% vs. 17.1%, p = 0.003) and a higher tumor mutation burden (TMB) compared to patients who harbored POLE wild-type tumors [11]. This evidence concerns the gene POLE and colorectal carcinoma.